Palvella Therapeutics (NASDAQ:PVLA – Get Free Report) Director George M. Jenkins purchased 4,000 shares of Palvella Therapeutics stock in a transaction dated Wednesday, December 18th. The stock was bought at an average cost of $12.93 per share, with a total value of $51,720.00. Following the completion of the transaction, the director now directly owns 180,671 shares of the company’s stock, valued at $2,336,076.03. This represents a 2.26 % increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.
Palvella Therapeutics Stock Performance
Palvella Therapeutics stock opened at $12.05 on Friday. Palvella Therapeutics has a 12 month low of $6.20 and a 12 month high of $22.32. The firm has a market cap of $15.91 million, a PE ratio of -1.00 and a beta of 0.61.
Wall Street Analyst Weigh In
Separately, Cantor Fitzgerald began coverage on shares of Palvella Therapeutics in a research note on Wednesday. They issued an “overweight” rating on the stock.
Featured Articles
- Five stocks we like better than Palvella Therapeutics
- Ride Out The Recession With These Dividend Kings
- Oil Titans Face Off: Exxon Mobil or Chevron for 2025 Gains?
- What Investors Must Know About Over-the-Counter (OTC) Stocks
- Mining Stocks Back in the Spotlight: 3 Key Names to Watch
- What Are Dividend Champions? How to Invest in the Champions
- MarketBeat Week in Review – 12/16 – 12/20
Receive News & Ratings for Palvella Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Palvella Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
